INTRODUCTION
The ovary is a major site of androstenedione (A) and testosterone (T) production. Approximately 50% of the total A production and 70% of the total production of T in a premenopausal woman is derived from the ovary. During controlled ovarian hyperstimulation with human menopausal gonadotropins (hMG) and, to a lesser extent, with purified folliclestimulating hormone (FSH), there is increased secretion of not only estrogens, but also androgens, namely, A and T (1-3). After hMG administration (on the day of hCG administration), serum T and A levels as high as 124 ng/dL and 411 ng/dL have been reported (1, 4) .
Androgens are cleared from the circulation by two major pathways. One pathway involves the enzyme, 5α-reductase, which converts A and T to the reduced metabolites, 5α-androstanedione and dihydrotestosterone (DHT), respectively. The other pathway involves transformation of A and T to estrone (E 1 ) and estradiol (E 2 ), respectively, through the action of the enzyme, aromatase. Aromatase is located in the granulosa cells and its activity is known to be enhanced by FSH (5) (6) (7) (8) . However, there is little information about 5α-reductase activity during ovarian hyperstimulation. It is also not clear how an increase in both estrogens and androgens would combine to influence androgen action. Estrogens would be expected to increase sex hormone-binding globulin (SHBG) and high luteal progesterone levels would be expected to compete with T and A for 5α-reductase. It is not clear how the net effect of these changes would affect androgen metabolism.
Therefore, the objective of the present study was to determine whether 1) the 5α-reductase pathway is altered with respect to T metabolism during ovarian hyperstimulation, and 2) changes in circulating SHBG levels occur during treatment.
MATERIALS AND METHODS
Five women, aged 33-42, were studied. All were undergoing controlled ovarian hyperstimulation using a gonadotropin-releasing hormone (GnRH) agonist and hMG stimulation in preparation for in vitro fertilization (IVF). All had regular menses and no evidence of polycystic ovaries. Leuprolide acetate (Lupron , TAP Pharmaceuticals, Deerfield, IL), 1.0 mg/day, was administered subcutaneously for 10 days beginning on day 21 of the menstrual cycle. After 10-14 days of GnRH-agonist treatment, serum levels of E 2 were measured. If serum E 2 levels were <30 pg/mL, hMG was administered intramuscularly daily, and the GnRH-agonist dose was decreased to 0.5 mg/day. After 5 days of hMG administration, follicular development was monitored in all patients by transvaginal ultrasound and serum E 2 levels. Follicular stimulation and monitoring continued until follicle maturity criteria (follicle diameter = 18 mm) were reached. At that time, human chorionic gonadotropin (hCG) 10,000 IU was administered intramuscularly. Oocyte recovery was performed 34-36 h after hCG administration. Embryo transfer was performed 3 days after follicle aspiration.
Blood samples were studied at 6 time points during the cycle: 1) prior to GnRH agonist in the midluteal phase (baseline); 2) after GnRH suppression (serum E 2 < 30 pg/mL); on day 1 of hMG; 3) in the follicular phase during hMG stimulation, 2 days prior to hCG administration; 4) on the day of, but prior to, hCG administration; 5) on the day of aspiration; and 6) 2 weeks postaspiration. The blood samples were allowed to clot, then were centrifuged, and stored at −15
• C until analyzed. Serum levels of A, T, E 1 , E 2 , SHBG, and 3α-androstanediol glucuronide, a distal metabolite of DHT and a specific marker of 5α-reductase activity (9), were quantified by specific radioimmunoassays (RIAs) as described previously (10-13). Prior to quantification of A, T, E 1 , and E 2 by RIA, steroids were first extracted with ether acetate:hexane, and the extracts were subjected to Celite-column partition chromatography. 3α-Androstanediol glucuronide and SHBG were measured by highly specific direct RIAs using commercial kits (Diagnostic Systems Laboratories, Webster, TX).
Aromatase activity was inferred from the ratios of E 1 /A and E 2 /T, whereas 5α-reductase activity was calculated as 3α-androstanediol glucuronide/T and 3α-androstanediol glucuronide/A. Steroid ratios have been used as a measure of enzyme activity, e.g., for 3β-hydroxysteroid dehydrogenase and 17,20-desmolase, when an effective assay does not exist to measure enzyme activity (14) (15) (16) (17) .
Significance of differences for each analyte over the time points tested was determined by analysis of variance. Data are shown as mean ± standard deviation.
RESULTS
The mean A, T, E 1 , E 2 , 3α-androstanediol glucuronide, and SHBG levels during the controlled ovarian hyperstimulation cycles are shown in Fig. 1 
(a)-(c).
During the hMG cycle, mean serum E 1 and E 2 levels increased significantly between baseline and day of aspiration (P = 0.002, P = <0.0001, respectively). Mean SHBG levels also followed this trend and increased significantly between these time points (P = 0.009).
Mean serum androgen levels, including T and A, and 3α-androstanediol glucuronide, also increased between baseline and day of aspiration (P = 0.001, P = 0.003, and P = 0.1, respectively).
The extent of aromatization of A and T to E 1 and E 2 can be assessed by the ratios of E 1 /A and E 2 /T, respectively. Both E 1 /A and E 2 /T increased dramatically from approximately 100 to 500 and 300 to 5000, respectively, between the time of GnRH suppression and the day of follicle aspiration ( Fig. 2(a) ). These changes were statistically significant (P = 0.008, P < 0.0001, respectively). Figure 2(b) shows the mean ratios of 3α-androstanediol glucuronide/T and (a) Mean serum estrone (E 1 ) and estradiol (E 2 ) levels during the hMG cycle. Blood samples were studied at 6 time points during the cycle: 1) midluteal phase; 2) after GnRH suppression; 3-4) follicular phase; 5) day of aspiration; and 6) 2 weeks postaspiration. ANOVA was done between time points 1 and 5 for E 2 and E 1 ( * P < 0.0001, * P = 0.002, respectively). (b) Mean serum testosterone (T), androstenedione (A) and 5α-androstane-3α,17β-diol glucuronide (3α-diol G) levels during the hMG cycle. Blood samples were studied at 6 time points during the cycle: 1) midluteal phase; 2) after GnRH suppression; 3-4) follicular phase; 5) day of aspiration; and 6) 2 weeks postaspiration. ANOVA was done between time points 1 and 5 for T, A, and 3α-diol G ( * P = 0.001, * P = 0.003, * P = 0.1, respectively). (c) Mean serum sex hormone-binding globulin (SHBG) levels during the hMG cycle. Blood samples were studied at 6 time points during the cycle: 1) midluteal phase; 2) after GnRH suppression; 3-4) follicular phase; 5) day of aspiration; and 6) 2 weeks postaspiration. ANOVA was done between time points 1 and 5 ( * P = 0.009). (a) Mean ratios of estrone (E 1 ) to androstenedione (A) (E 1 /A) and estradiol (E 2 ) to testosterone (T) (E 2 /T) during the hMG cycle. Blood samples were studied at 6 time points during the cycle: 1) midluteal phase; 2) after GnRH suppression; 3-4) follicular phase; 5) day of aspiration; and 6) 2 weeks postaspiration. ANOVA was done between time points 1 and 5 for E 1 /A ( * P = 0.008, * P < 0.0001, respectively). (b) Mean ratios of 3α-androstanediol glucuronide (3α-diol G) to androstenedione (A) (3α-diol G/A) and 3α-diol G to testosterone (T) (3α-diol G/T) during the hMG cycle. Blood samples were studied at 6 time points during the cycle: 1) midluteal phase; 2) after GnRH suppression; 3-4) follicular phase; 5) day of aspiration; and 6) 2 weeks postaspiration. ANOVA was done between time points 1 and 5 for 3α-diol G/A and 3α-diol G/T ( * P < 0.05, * P = 0.09, respectively). 3α-androstanediol glucuronide/A, which represent the 5α-reduction pathways during exogenous hMG stimulation. There was a statistically significant decrease for 3α-androstanediol glucuronide/A (P < 0.05) from 2.6 to 1.5 between the time of GnRH suppression and the day of aspiration. 3α-androstanediol glucuronide/T decreased from 9.6 to 6.2 (P = 0.09), between the time of GnRH suppression and the day of aspiration.
DISCUSSION
We found that controlled ovarian hyperstimulation was associated with an increase in serum levels of all of the steroids measured. As expected, mean E 1 and E 2 levels were suppressed during down-regulation with the GnRH agonist, and increased during the follicular phase with exogenous gonadotropin stimulation ( Fig. 1(a) ). After aspiration, the levels decreased to baseline values. T and A levels were suppressed during GnRH suppression and increased during follicular exogenous gonadotropin stimulation, peaking at mean levels of 0.58 ng/mL and 2.8 ng/mL, respectively ( Fig. 1(b) ). This elevation in ovarian androgens is not surprising. Levels of T and A as high as 1.24 ng/mL and 4.11 ng/mL, which are approximately twice as high as the mean levels in our study, have been reported (1) . Free T levels in conjunction with total T levels, have also been reported to rise during controlled ovarian hyperstimulation, despite increased SHBG levels (1). The elevation of both free and total T most likely results from ovarian stimulation by the LH component of urinary gonadotropin preparations (18) . It is intriguing that T and A are increased in spite of the short half-life of LH in hMG, and how little LH is needed to stimulate folliculogenesis. Gelety and Surrey (3) reported that GnRH agonists used prior to controlled ovarian hyperstimulation may result in incomplete suppression of circulating progesterone and androgens. These relative elevations, occurring early in the development of the follicular cohort, did not appear to affect IVF cycle outcome (3). Interestingly, we found that 3α-androstanediol glucuronide levels increased during GnRH suppression, and decreased prior to increasing during follicular exogenous gonadotropin stimulation ( Fig. 1(b) ). We speculate that this lag in response is due to the 5α-reduction of T and A prior to subsequent suppression of androgen levels and the long half-life of 3α-androstanediol glucuronide.
As anticipated, SHBG levels were found to decrease during GnRH suppression, and increase during follicular exogenous gonadotropin stimulation ( Fig. 1(c) ). It was of interest to note the elevation of SHBG levels during controlled ovarian hyperstimulation, in the face of elevations in both the androgens and estrogens. Androgens and estrogens have opposing individual effects on SHBG levels, with androgens causing a decrease and estrogens stimulating SHBG production (19, 20) . The increase in SHBG levels suggests that SHBG production is more dependent on estrogen than on androgen stimulation. We found that SHBG levels continued to increase after aspiration, despite decreasing E 2 levels. This continued rise in SHBG may well act to decrease the amount of bioavailable T at the time of implantation, since SHBG preferentially binds androgens over E 2 .
Although the sample size is small, all of the individual patients had similar hormone trends. The coefficient of variation was <30% at each time point studied. Despite the disparity in age range between the patients (9 years), all of the individual hormone curves followed the same trend. Therefore, although the older participants generally had lower hormone levels, their hormone and pathway curves all followed the same trend as with the younger participants curves.
Of the 5 patients studied, 2 achieved pregnancy and 3 did not achieve pregnancy. There was no difference in hormone and/or pathway curves between the conception and nonconception cycles.
We did not find any correlation with androgen levels and oocyte quality. All of our androgen levels were within the physiologic range of premenopausal women; however, the highest testosterone concentration was 65 ng/dL.
Our data are consistent with the enhancement of the aromatase pathway during controlled ovarian hyperstimulation, whereas the 5α-reductase pathway was inhibited. This demonstrates that androgens are preferentially metabolized via the aromatase pathway during controlled ovarian hyperstimulation. Although it is not surprising that the aromatase pathway predominates, it is interesting that 5α-reductase activity is suppressed with regard to androgen metabolism. This suggests that the actual conversion of A and T to DHT is not solely substrate dependent. It is possible that 5α-reductase activity is modulated by competitive inhibitors, such as progesterone (21) . Krieg et al. (22) investigated 5α-reductase in benign prostatic hyperplasia and found the mean inhibitor constants of progesterone, E 1 , and E 2 , with regard to 5α-reductase activity, to be 0.11, 15.5, and 5.1, respectively. Thus, if the mean inhibitor constants for 5α-reductase in ovarian tissue resemble those of prostatic tissue, supraphysiologic concentrations of progesterone, E 1 , and E 2 obtained during controlled ovarian hyperstimulation could exceed the inhibitor constants for 5α-reductase, thereby inhibiting the activity of this enzyme. A number of prior reports have substantiated 5α-reductase modulation by sex steroids (21) (22) (23) (24) (25) (26) . Cassidenti et al. (21) have shown in vitro, that E 2 , progesterone, and the 19-nor-progestins inhibit the conversion of T to DHT in genital skin at high doses. E 2 , progesterone, levonorgestrel, and norethindrone demonstrated 40.8 ± 14.2%, 97 ± 5.3%, 47.9 ± 6.3%, and 59 ± 4.6% inhibition, respectively. In addition, the suggestion has been made that prenatal exposure to synthetic progestins contributes to an increased incidence of hypospadias (26) . One potential mechanism for such an effect may be competitive inhibition of 5α-reductase.
Exogenous progesterone administered in the luteal phase after IVF could also cause decreased conversion of androstenedione and testosterone to dihydrotestosterone. The clinical relevance of various androgen concentrations on the endometrium is not known.
We conclude that although androgen levels increase during controlled ovarian hyperstimulation, androgen metabolism engenders a less androgenic milieu. This is due to increased aromatase activity, and increased SHBG levels, which decrease free T levels. By contrast, androgen metabolism by 5α-reductase is decreased, possibly as a result of the presence of high levels of other steroids.
